The decision means that UnitedHealthcare's members will have access to Biodesix's test for advanced NSCLC as a covered benefit.
The proteomics test to guide treatment of non-small cell lung cancer will be covered for 3.4 million patients in Maryland, DC, and Virginia.
The study found that using Veristrat to guide patient therapy decreased the total lifetime direct medical cost per patient by $135.
The company cited as likely applications development of tests for guiding therapy in late-stage patients and support of drug development efforts.
The deal will leverage Inivata's technology platform and Biodesix's development and commercialization capabilities in the US.
The company plans to launch a PCR-based test for measuring three genes in the plasma of lung cancer patients and is also at work on an NGS-based panel.
Biodesix will use the investment to continue development of its blood-based molecular diagnostic technology platform and test menu.
NEW YORK (GenomeWeb) – The National Comprehensive Cancer Network has approved inclusion of Biodesix's VeriStrat proteomics test in its guidelines for non-small cell lung cancer, the Boulder, Colo.-based firm said today.
Agilent Technologies said this week that it has awarded its Agilent Thought Leader Award to Carlos Cordon-Cardo, a molecular pathologist at Mount Sinai Hospital
NEW YORK (GenomeWeb) – Biodesix said today that it has received a positive coverage decision from Highmark, a Blue Cross Blue Shield affiliate, for its Veristrat lung cancer test.
The Wall Street Journal looks into FamilyTreeDNA's handling of genetic genealogy searches by law enforcement.
In a point-counterpoint in the Boston Globe, researchers discuss the potential of gene editing to prevent Lyme disease, but also the pitfalls of doing so.
MIT's Technology Review reports that researchers hope to develop a CRISPR-based pain therapy.
In Science this week: atlas of malaria parasites' gene expression across their life cycles, and more.